Pharmaceutical companies are scrambling to focus on the development of innovative therapies, and a large number of patients will benefit in the future

According to data, in 2021, the FDA approved a total of 50 innovative treatments (53 in the same period last year)

In this regard, the industry believes that from the above data, it can be clearly seen that the industry is currently enthusiastic about the research and development of innovative therapies

In addition to the above-mentioned drugs, it is worth mentioning that, according to the statistics of the "Nature" journal report, 18 innovative treatments will be launched in 2022 and are worthy of attention

The industry believes that the reason why innovative therapies have become the current research and development focus of pharmaceutical companies is that it is easier for innovative therapies to obtain special qualifications from the FDA, which can speed up the review of therapies; and innovative therapies are the treatment of patients with specific genetic variants.

It is worth mentioning that, on the whole, CAR-T and ADC have become the main focus of pharmaceutical companies in innovative therapies

According to data, domestic pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years

In addition, ADC is also a therapy that has received a lot of attention